ApicHope Pharmaceutical (SHE:300723), through a subsidiary, received approval from China's National Medical Products Administration for the Qinxiang Qingjie Oral Liquid to become a Class II protected traditional Chinese medicine variety, according to a Shenzhen bourse disclosure on Saturday.
The pharmaceutical company's shares dipped 20% at the close of Monday's trade.
The drug is mainly used for children with upper respiratory tract infections with symptoms of both external and internal heat.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments